Skip to content

Investor Relations / Publications / Scientific Presentations at Society Meetings

Scientific Presentations at Society Meetings

To search publications using the available search words, please click here:

Reduction in total ischemic events in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

American College of Cardiology

Bhatt DL, Steg G, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif J-C, Gregson J, Pocock SJ, Ballantyne CM, on behalf of the REDUCE-IT Investigators. Reduction in total ischemic events in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial. Presented at the annual meeting of the American College of Cardiology, March 16-18, 2019, New Orleans, Louisiana.

Toth P, Granowitz C, Hull M, Philip S. Long-term statin persistence is poor among high-risk patients with baseline peripheral artery disease: a real-world administrative claims analysis of the Optum research database [abstract]. J Am Coll Cardiol. 2019;73:1744.

http://www.onlinejacc.org/content/73/9_Supplement_1/1744
Leatherman S, Ferguson R, Weir I, et al. Increased residual cardiovascular risk in US veterans and moderately-elevated baseline triglycerides and well-controlled LCL-C levels on statins [abstract]. J Am Coll Cardiol. 2019;73:1719. http://www.onlinejacc.org/content/73/9_Supplement_1/1719

Toth P, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. Long-term renal function worsens in high cardiovascular risk patients with high triglycerides and well-controlled low-density lipoprotein cholesterol in a real-world analysis [abstract]. J Am Coll Cardiol. 2018;71(11 suppl):A1445.

http://www.onlinejacc.org/content/71/11_Supplement/A1445
Miller M, Ballantyne C, Bays H, Granowitz C, Doyle R, Juliano R, Philip S. Icosapent ethyl (eicosapentaenoic acid ethyl ester) reduces potentially atherogenic lipid, lipoprotein, apolipoprotein, and inflammatory parameters in high-risk, statin-treated patients with persistent elevated triglycerides and high-sensitivity C-reactive protein: a post hoc subanalysis of the ANCHOR study [abstract]. J Am Coll Cardiol. 2018;71(11 suppl):A1392. http://www.onlinejacc.org/content/71/11_Supplement/A1392
Bays HE, Philip S, Chowdhury S, Doyle R, Juliano RA. Icosapent ethyl (eicosapentaenoic acid ethyl ester) in statin-treated patients with elevated cardiovascular risk and very high triglyceride levels: results from the MARINE study [abstract]. J Am Coll Cardiol. 2016;67(suppl):1950. http://www.onlinejacc.org/content/67/13_Supplement/1950

American Heart Association
Budoff MJ, Muhlestein JB, Bhatt DL, Le VT, May HT, Shaikh K, Shekar C, Kinninger A, Lakshmanan S, Roy S, Tayek J, Nelson JR. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy (EVAPORATE study) [abstract]. Presented at: Annual Scientific Sessions of the American Heart Association; November 16-18, 2019, 2019; Philadelphia, PA.

https://www.abstractsonline.com/pp8/#!/7891/presentation/35090

Melendez GC, Medina-Hernandez D, Pflum AW, Xu V, Herrington DM. Purified eicosapentaenoic acid ameliorates cardiac fibrosis and tissue inflammation in spontaneously hypertensive rats [abstract]. Circulation. 2019;140(suppl 1):A13892.

https://www.abstractsonline.com/pp8/#!/7891/presentation/28631

Weintraub WS, Bhatt DL, Zhang Z, Dolman SF, Zhang C, Boden II WE, Bress AP, King JB, Steg PG, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Kolm P. Cost-effectiveness of icosapent ethyl in REDUCE-IT [abstract]. Presented at: Annual Scientific Sessions of the American Heart Association; November 16-18, 2019, 2019; Philadelphia, PA.

https://www.abstractsonline.com/pp8/#!/7891/presentation/35097

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum S, Doyle R, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM. REDUCE-IT USA: results from the 3,146 patients drandomized in the United States [abstract]. Presented at: Annual Scientific Sessions of the American Heart Association; November 16-18, 2019, 2019; Philadelphia, PA.

https://www.abstractsonline.com/pp8/#!/7891/presentation/40313
Icosapent ethyl reduces potentially atherogenic lipid and inflammatory markers in high-risk statin-treated patients with stage 3 chronic kidney disease and persistent high triglycerides
Vijayaraghavan K, Szerlip HM, Ballantyne CM, Bays HE, Philip S, Doyle RT, Juliano RA, Granowitz C. Icosapent ethyl reduces potentially atherogenic lipid and inflammatory markers in high-risk statin-treated patients with stage 3 chronic kidney disease and persistent high triglycerides [abstract]. Circulation. 2017;136(suppl 1):A15097.
Effects of AMR101, a pure eicosapentaenoic omega-3 fatty acid, on the fatty acid profile in plasma and red blood cells in statin-treated patients with persistent high triglycerides (results from the ANCHOR study)

Braeckman RA, Manku MS, Ballantyne CM, Stirtan WG, Soni PN. Effects of AMR101, a pure eicosapentaenoic omega-3 fatty acid, on the fatty acid profile in plasma and red blood cells in statin-treated patients with persistent high triglycerides (results from the ANCHOR study) [abstract]. Circulation. 2012;126:A18549.

Pagidipati N, Navar A, Mulder H, Wojdyla DM, Philip S, Granowitz CB. Association between triglycerides and residual cardiovascular (CVD) risk in patients with type 2 diabetes and established CVD: an analysis of the BARI2D trialDiabetes. 2019;68(suppl 1):1472P.

http://diabetes.diabetesjournals.org/content/68/Supplement_1/1472-P
The triglyceride-lowering effects of icosapent ethyl (pure eicosapentaenoic acid ethyl ester) correlate with reductions in ASCVD risk factors commonly found in hypertriglyceridemic patients.

American Society for Preventive Cardiology
Bays HE, Ballantyne CM, Philip S, Juliano RA, Doyle RT, Granowitz CG.
The triglyceride-lowering effects of icosapent ethyl (pure eicosapentaenoic acid ethyl ester) correlate with reductions in ASCVD risk factors commonly found in hypertriglyceridemic patients.
Presented at: The American Society for Preventive Cardiology, July 27-29, 2018, Santa Ana Pueblo, NM. 

Eicosapentaenoic acid inhibited oxidized HDL-induced loss of endothelial nitric oxide release as compared to fenofibrate or niacin in vitro

European Atherosclerosis Society
Mason RP, Sherratt SCR, Malinski T. Eicosapentaenoic acid inhibited oxidized HDL-induced loss of endothelial nitric oxide release as compared to fenofibrate or niacin in vitroPresented at: The European Atherosclerosis Society Congress, May 5-8, 2018, Lisbon, Portugal.

Mason R, Sherratt S. Eicosapentaenoic Acid (EPA) Inhibits Human Low-Density Lipoprotein Oxidation in a Concentration- And Time-Dependent Manner at Pharmacologic Doses In Vitro [abstract EAS19-0568]. Atherosclerosis. 2019; in press.

https://www.atherosclerosis-journal.com/article/S0021-9150(19)30687-2/fulltext
Eicosapentaenoic acid exposure lowers triglycerides without raising LDL-C by slowing TRL production and hastening LDL clearance in patients with residual triglyceridemia

Gordon Conference on Atherosclerosis
Dunbar RL, Copland C, Jiao L, Wang R, Wong K, Millar JS, Escobar M, Siri-Tarino P, Juliano RA. Eicosapentaenoic acid exposure lowers triglycerides without raising LDL-C by slowing TRL production and hastening LDL clearance in patients with residual triglyceridemia. Poster presented at the Gordon Conference on Atherosclerosis, June 16-21, 2019, Newry, Maine.

Comparing eicosapentaenoic acid between plasma and serum from a randomized, controlled clinical trial

Dunbar RL, Copland C, Jiao L, Wang R, Wong K, Millar JS, Escobar M, Siri-Tarino P, Juliano RA. Comparing eicosapentaenoic acid between plasma and serum from a randomized, controlled clinical trial. Poster presented at the Gordon Conference on Atherosclerosis, June 16-21, 2019, Newry, Maine.

Effects of icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, on the fatty acid profile in plasma and red blood cells in statin-treated patients with persistent high triglycerides (results from the ANCHOR study) 

Kern Lipid Conference
Abstracts are not published – approved to post to Amarin’s website
Juliano RA, Braeckman RA, Manku MS, Ballantyne CM, Doyle RT Jr, Soni PN, Stirtan WG. Effects of icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, on the fatty acid profile in plasma and red blood cells in statin-treated patients with persistent high triglycerides (results from the ANCHOR study) [abstract]. Presented at: The Kern Lipid Conference, August 3-4, 2015, Vail, Colorado.

Eicosapentaenoic acid is a strong predictor of risk for heart failure in the multi-ethnic study of atherosclerosis

PI|LIFESTYLE (Epidemiology and Prevention | Lifestyle and Cardiometabolic Health)
Robert RC, Liu L, Tsai MY, O'Connell TD, Shearer GC. Eicosapentaenoic acid is a strong predictor of risk for heart failure in the multi-ethnic study of atherosclerosis. Circulation . 2018;137:A026.

Eicosapentaenoic acid inhibits oxidation of small dense LDL in a manner distinct from related fatty acids in vitro

International Society for the Study of Fatty Acids and Lipids
Sherratt SCR, Mason RP. Eicosapentaenoic acid inhibits oxidation of small dense LDL in a manner distinct from related fatty acids in vitro [poster]. Presented at: The Congress of the International Society for the Study of Fatty Acids and Lipids, Las Vegas, Nevada, May 27-31, 2018.

The potential of electronic health record data to optimize recruitment efficiency in cardiovascular outcome trials

International Society for Pharmacoeconomics and Outcomes Research
Nichols GA, Reynolds K, Philip S, Granowitz C, Fazio S. The potential of electronic health record data to optimize recruitment efficiency in cardiovascular outcome trials [abstract PRM9]. Value Health. 2017;20:A312.

Predictive modeling to assess predictors of treatment success and failure among combination statin therapy patients

Nyandege A, Burudpakdee C, Philip S. Predictive modeling to assess predictors of treatment success and failure among combination statin therapy patients [abstract PRM20]. Value Health. 2014;17:A546.

National Lipid Association
Lee A, Kinninger A, Jayawardena E, Shekar C, Cherukuri L, Dailing C, Hamal S, Flores F, Budoff M, Nelson J. Relationship between lipid levels and coronary atherosclerotic plaque scores by coronary computed tomography angiography (CTA) in subjects with elevated triglyceridesJ Clin Lipidol. 2019.

https://www.lipidjournal.com/article/S1933-2874(19)30125-4/fulltext

Cherukuri L, Shekar C, Kinninger A, Birudaraju D, Hamal S, Flores F, Tayek J, Roy S, Budoff M, Nelson J, Johanis A. Comparison of atherosclerotic plaque characteristics among normal and high triglycerides (TGs) patientsJ Clin Lipidol. 2019; epub ahead of print.
https://www.lipidjournal.com/article/S1933-2874(19)30118-7/fulltext

https://www.lipidjournal.com/article/S1933-2874(19)30118-7/fulltext
Managing the lipid triad: improving physicians' understanding of the role of omega-3 fatty acids with CME
Larkin AT, Healy CS. Managing the lipid triad: improving physicians' understanding of the role of omega-3 fatty acids with CME [abstract 177]. J Clin Lipidol. 2015;9:466-7.

National Kidney Foundation
Szerlip HM, Vijay K, Ballantyne CM, Bays HE, Granowitz C, Doyle RT, Juliano RA, Philip S. Icosapent ethyl reduces potentially atherogenic lipid and inflammatory markers in high-risk statin-treated patients with persistent high triglycerides, EGFR <90 mL/min/1.73 m2, and diabetes mellitus [abstract 295]. Am J Kidney Dis.2018;71(4):589.

http://www.ajkd.org/article/S0272-6386(18)30432-3/fulltext

Vijay K, Szerlip HM, Ballantyne CM, Nelson JR, Granowitz C, Doyle RT, Juliano RA, Philip S. Icosapent ethyl reduces potentially atherogenic lipid and inflammatory markers in high-risk statin-treated patients with persistent high triglycerides, EGFR <90 mL/min/1.73 m2, and elevated high-sensitivity C-reactive protein =2.0 mg/L [abstract 317]. Am J Kidney Dis. 2018;71(4):594-595.

http://www.ajkd.org/article/S0272-6386(18)30454-2/fulltext

Obesity Society
Kedia AW, Lynch E. Omega-3 fatty acid treatment in an obese patient with hypertension and persistently elevated triglycerides despite statin therapy: reductions in triglycerides and low-density lipoprotein cholesterol and improvements in other lipid parameters following switch from omega-3 fatty acid ethyl esters to icosapent ethyl [abstract]. Presented at: the Annual Obesity Week meeting, November 2-7, 2015, Los Angeles, California.
Available online at: Page S154 

https://www.ncbi.nlm.nih.gov/pubmed/26453247

Amarin Corporation